Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 1561 AL 1575

From Research to Application: Supportive and Therapeutic Environments for People Living With Dementia

Calkins MP.

Gerontologist. 2018 Jan 18;58(suppl_1):S114-S128. doi: 10.1093/geront/gnx146.

Meeting the Informational, Educational, and Psychosocial Support Needs of Persons Living With Dementia and Their Family Caregivers

Whitlatch CJ, Orsulic-Jeras S.

Gerontologist. 2018 Jan 18;58(suppl_1):S58-S73. doi: 10.1093/geront/gnx162.

Can Exercise Improve Cognitive Symptoms of Alzheimer's Disease?

Panza GA, Taylor BA, MacDonald HV, Johnson BT, Zaleski AL, Livingston J, Thompson PD, Pescatello LS.

J Am Geriatr Soc. 2018 Mar;66(3):487-495. doi: 10.1111/jgs.15241. Epub 2018 Jan 24.

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease

Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E.

N Engl J Med. 2018 Jan 25;378(4):321-330. doi: 10.1056/NEJMoa1705971.

Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions

Geifman N, Kennedy RE, Schneider LS, Buchan I, Brinton RD.

Alzheimers Res Ther. 2018 Jan 15;10(1):4. doi: 10.1186/s13195-017-0332-0.

Exercise Training on Locomotion in Patients with Alzheimer's Disease: A Feasibility Study

Pedrinolla A, Venturelli M, Fonte C, Munari D, Benetti MV, Rudi D, Tamburin S, Muti E, Zanolla L, Smania N, Schena F.

J Alzheimers Dis. 2018;61(4):1599-1609. doi: 10.3233/JAD-170625.

Safety, tolerability and immunogenicity of an active anti-Aβ(40) vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta AM, Pascual-Lucas M, Pesini P, Casabona D, Pérez-Grijalba V, Marcos-Campos I, Sarasa L, Canudas J, Badi H, Monleón I, San-José I, Munuera J, Rodríguez-Gómez O, Abdelnour C, Lafuente A, Buendía M, Boada M, Tárraga L, Ruiz A, Sarasa M.

Alzheimers Res Ther. 2018 Jan 29;10(1):12. doi: 10.1186/s13195-018-0340-8.

Socioeconomic disparities in clinical trials on Alzheimer's disease: a systematic review

Canevelli M, Bruno G, Vico C, Zaccaria V, Lacorte E, Iavicoli I, Vanacore N, Cesari M.

Eur J Neurol. 2018 Apr;25(4):626-e43. doi: 10.1111/ene.13587. Epub 2018 Feb 26.

Peptides as Potential Therapeutics for Alzheimer's Disease

Ribarič S.

Molecules. 2018 Jan 30;23(2):283. doi: 10.3390/molecules23020283.

Deep Brain Stimulation of Frontal Lobe Networks to Treat Alzheimer's Disease

Scharre DW, Weichart E, Nielson D, Zhang J, Agrawal P, Sederberg PB, Knopp MV, Rezai AR; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;62(2):621-633. doi: 10.3233/JAD-170082.

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease

Liu-Seifert H, Case MG, Andersen SW, Holdridge KC, Aisen PS, Kollack-Walker S, Siemers E.

J Prev Alzheimers Dis. 2018;5(1):8-14. doi: 10.14283/jpad.2018.1.

Research and development of anti-Alzheimer's disease drugs: an update from the perspective of technology flows

Liu K, Lin HH, Pi R, Mak S, Han Y, Hu Y.

Expert Opin Ther Pat. 2018 Apr;28(4):341-350. doi: 10.1080/13543776.2018.1439475. Epub 2018 Feb 13.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias